PIK3CA and ovarian carcinoma: In a phase II trial in patients with advanced solid malignancies with PI3K/AKT pathway abnormalities, TAS-117 showed anti-tumour activity in patients with PIK3CA H1047R and AKT1E17K-mutated breast cancer and PIK3CA E545K-mutated ovarian cancer.